Concentration-dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells
Ravera, Silvia et al. (2018),
Journal of Cellular Physiology,
vol. 233,
1736-1751
Ravera, Silvia, Cossu, Vanessa, Tappino, Barbara, Nicchia, Elena, Dufour, Carlo, Cavani, Simona, Sciutto, Andrea, Bolognesi, Claudia, Columbaro, Marta, Degan, Paolo, Cappelli, Enrico (2018),
Journal of Cellular Physiology,
vol.
233,
1736-1751
Metformin (MET) is the drug of choice for patients with type 2 diabetes and has been proposed for use in cancer therapy and for treating other metabolic diseases. More than 14,000 studies have been published addressing the cellular mechanisms affected by MET. However, several in vitro studies have used concentrations of the drug 10–100-fold higher than the plasmatic concentration measured in patients. Here, we evaluated the biochemical, metabolic, and morphologic effects of various concentrations of MET. Moreover, we tested the effect of MET on Fanconi Anemia (FA) cells, a DNA repair genetic disease with defects in energetic and glucose metabolism, as well as on human promyelocytic leukemia (HL60) cell lines. We found that the response of wild-type cells to MET is concentration dependent. Low concentrations (15 and 150 µM) increase both oxidative phosphorylation and the oxidative stress response, acting on the AMPK/Sirt1 pathway, while the high concentration (1.5 mM) inhibits the respiratory chain, alters cell morphology, becoming toxic to the cells. In FA cells, MET was unable to correct the energetic/respiratory defect and did not improve the response to oxidative stress and DNA damage. By contrast, HL60 cells appear sensitive also at 150 μM. Our findings underline the importance of the MET concentration in evaluating the effect of this drug on cell metabolism and demonstrate that data obtained from in vitro experiments, that have used high concentrations of MET, cannot be readily translated into improving our understanding of the cellular effects of metformin when used in the clinical setting.
10.1002/jcp.26085
Renal Energy Metabolism Following Acute Dichloroacetate and 2,4-Dinitrophenol Administration: Assessing t…
Bertelsen, Lotte Bonde et al. (2018),
Tomography (Ann Arbor, Mich.),
vol. 4,
105-109
Bertelsen, Lotte Bonde, Nielsen, Per Mose, Qi, Haiyun, Mariager, Christian Østergaard, Lindhardt, Jakob, Laustsen, Christoffer (2018),
Tomography (Ann Arbor, Mich.),
vol.
4,
105-109
Numerous patient groups receive >1 medication and as such represent a potential point of improvement in today's healthcare setup, as the combined or cumulative effects are difficult to monitor in an individual patient. Here we show the ability to monitor the pharmacological effect of 2 classes of medications sequentially, namely, 2,4-dinitrophenol, a mitochondrial uncoupler, and dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, both targeting the oxygen-dependent energy metabolism. We show that although the 2 drugs target 2 different metabolic pathways connected ultimately to oxygen metabolism, we could distinguish the 2 in vivo by using hyperpolarized [1-13C]pyruvate magnetic resonance imaging. A statistically significantly different pyruvate dehydrogenase flux was observed by reversing the treatment order of 2,4-dinitrophenol and dichloroacetate. The significance of this study is the demonstration of the ability to monitor the metabolic cumulative effects of 2 distinct therapeutics on an in vivo organ level using hyperpolarized magnetic resonance imaging.
10.18383/j.tom.2018.00022
808-Nm Photobiomodulation Affects the Viability of a Head and Neck Squamous Carcinoma Cellular Model, Act…
Ravera, Silvia et al. (2021),
Biomedicines,
vol. 9,
1-16
Ravera, Silvia, Bertola, Nadia, Pasquale, Claudio, Bruno, Silvia, Benedicenti, Stefano, Ferrando, Sara, Zekiy, Angelina, Arany, Praveen, Amaroli, Andrea (2021),
Biomedicines,
vol.
9,
1-16
Photobiomodulation (PBM) is a form of low-dose light therapy that acts through energy delivery from non-ionizing sources. During the recent two decades, there has been tremendous progress with PBM acceptance in medicine. However, PBM effects on potential stimulation of existing malignant or pre-malignant cells remain unknown. Thus, the primary endpoint was to assess the safety of PBM treatment parameters on head and neck squamous cell carcinoma (HNSCC) proliferation or survival. The secondary endpoint was to assess any putative anti-cancer effects of PBM treatments. Cell viability, energy metabolism, oxidative stress, and pro-and anti-apoptotic markers expression were investigated on a Human Head and Neck Squamous Cell Carcinoma cellular model (OHSU-974 FAcorr cell line). PBM therapy was administered through the 810 nm diode laser (GaAlAs) device (Garda Laser, 7024 Negrar, Verona, Italy) at the powers of 0, 0.25, 0.50, 0.75, 1.00, or 1.25 W in continuous wave (CW) mode for an exposure time of 60 s with a spot-size of 1 cm2 and with a distance of 1.86 cm from the cells. Results showed that 810-nm PBM affected oxidative phosphorylation in OHSU-971 FAcorr, causing a metabolic switch to anaerobic glycolysis. In addition, PBM reduced the catalase activity, determining an unbalance between oxidative stress production and the antioxidant defenses, which could stimulate the pro-apoptotic cellular pathways. Our data, at the parameters investigated, suggest the safeness of PBM as a supportive cancer therapy. Preclinical and clinical studies are necessary to confirm the in vitro evidence.
10.3390/biomedicines9111717
The human fetal and adult stem cell secretome can exert cardioprotective paracrine effects against cardio…
Villa, Federico et al. (2021),
Cancers,
vol. 13,
-
Villa, Federico, Bruno, Silvia, Costa, Ambra, Li, Mingchuan, Russo, Michele, Cimino, James, Altieri, Paola, Ruggeri, Clarissa, Gorgun, Cansu, De Biasio, Pierangela, Paladini, Dario, Coviello, Domenico, Quarto, Rodolfo, Ameri, Pietro, Ghigo, Alessandra, Ravera, Silvia, Tasso, Roberta, Bollini, Sveva (2021),
Cancers,
vol.
13,
-
Cardiovascular side effects are major shortcomings of cancer treatments causing cardiotox-icity and late-onset cardiomyopathy. While doxorubicin (Dox) has been reported as an effective chemotherapy agent, unspecific impairment in cardiomyocyte mitochondria activity has been docu-mented. We demonstrated that the human fetal amniotic fluid-stem cell (hAFS) secretome, namely the secreted paracrine factors within the hAFS-conditioned medium (hAFS-CM), exerts pro-survival effects on Dox-exposed cardiomyocytes. Here, we provide a detailed comparison of the cardiopro-tective potential of hAFS-CM over the secretome of mesenchymal stromal cells from adipose tissue (hMSC-CM). hAFS and hMSC were preconditioned under hypoxia to enrich their secretome. The cardioprotective effects of hAFS/hMSC-CM were evaluated on murine neonatal ventricular cardiomy-ocytes (mNVCM) and on their fibroblast counterpart (mNVFib), and their long-term paracrine effects were investigated in a mouse model of Dox-induced cardiomyopathy. Both secretomes significantly contributed to preserving mitochondrial metabolism within Dox-injured cardiac cells. hAFS-CM and hMSC-CM inhibited body weight loss, improved myocardial function, reduced lipid peroxidation and counteracted the impairment of mitochondrial complex I activity, oxygen consumption, and ATP synthesis induced by Dox. The hAFS and hMSC secretomes can be exploited for inhibiting cardiotoxic detrimental side effects of Dox during cancer therapy, thus ensuring cardioprotection via combinatorial paracrine therapy in association with standard oncological treatments.
10.3390/cancers13153729
Curcumin induces a fatal energetic impairment in tumor cells in vitro and in vivo by inhibiting ATP-synthase activity
Bianchi, Giovanna et al. (2018),
Carcinogenesis,
vol. 39,
1141-1150
Bianchi, Giovanna, Ravera, Silvia, Traverso, Chiara, Amaro, Adriana, Piaggio, Francesca, Emionite, Laura, Bachetti, Tiziana, Pfeffer, Ulrich, Raffaghello, Lizzia (2018),
Carcinogenesis,
vol.
39,
1141-1150
Curcumin has been reported to inhibit inflammation, tumor growth, angiogenesis and metastasis by decreasing cell growth and by inducing apoptosis mainly through the inhibition of nuclear factor kappa-B (NFκB), a master regulator of inflammation. Recent reports also indicate potential metabolic effects of the polyphenol, therefore we analyzed whether and how it affects the energy metabolism of tumor cells. We show that curcumin (10 µM) inhibits the activity of ATP synthase in isolated mitochondrial membranes leading to a dramatic drop of ATP and a reduction of oxygen consumption in in vitro and in vivo tumor models. The effects of curcumin on ATP synthase are independent of the inhibition of NFκB since the IκB Kinase inhibitor, SC-514, does not affect ATP synthase. The activities of the glycolytic enzymes hexokinase, phosphofructokinase, pyruvate kinase and lactate dehydrogenase are only slightly affected in a cell type-specific manner. The energy impairment translates into decreased tumor cell viability. Moreover, curcumin induces apoptosis by promoting the generation of reactive oxygen species (ROS) and malondialdehyde (MDA), a marker of lipid oxidation, and autophagy, at least in part due to the activation of the AMP-activated protein kinase (AMPK). According to the in vitro anti-tumor effect, curcumin (30 mg/kg body weight) significantly delayed in vivo cancer growth likely due to an energy impairment but also through the reduction of tumor angiogenesis. These results establish the ATP synthase, a central enzyme of the cellular energy metabolism, as a target of the antitumoral polyphenol leading to inhibition of cancer cell growth and a general reprogramming of tumor metabolism.
10.1093/carcin/bgy076
The effect of 2-Deoxy-D-glucose on glycolytic metabolism in acute myeloblastic leukemic ML-1 cells
Christensen, Nichlas Vous et al. (2025),
Scientific Reports,
vol. 15,
-
Christensen, Nichlas Vous, Knudsen, Johanne Haahr, Laustsen, Christoffer, Bertelsen, Lotte Bonde (2025),
Scientific Reports,
vol.
15,
-
Acute myeloblastic leukemia (AML) is one of the most common and life-threatening forms of leukemia. Treatment remains challenging due to its high heterogeneity, drug resistance, and metabolic flexibility. Targeting specific metabolic pathways has emerged as a promising therapeutic approach. The ability to monitor treatment response is crucial for disease management. Here, we utilized hyperpolarized 13C nuclear magnetic resonance (NMR) spectroscopy to evaluate the therapeutic effects of 2-deoxy-D-glucose (2-DG), a glucose analog known to inhibit glycolysis and induce cell death in leukemic cell lines. Hyperpolarized 13C NMR spectroscopy, biochemical assays, and respirometry were used to assess the metabolic effects of 2-DG treatment at various concentrations on the AML cell line ML-1 in vitro. Significant metabolic alterations were observed following 2-DG treatment at 2 mM and 5 mM for 24 h, as revealed by multiple analytical approaches. The concentration-dependent effects of 2-DG treatment were clearly detected using hyperpolarized NMR, demonstrating substantial inhibition of glycolytic pathways in ML-1 cells. This study supports the potential of 2-DG for enhancing chemosensitivity in AML treatment and highlights hyperpolarized NMR as a valuable tool for therapy evaluation.
10.1038/s41598-025-01402-7